Effects of early estradiol valerate administration on bone turnover markers in surgically induced menopausal women

Abstract Background Compared with a natural process, surgically induced menopausal women have a higher bone loss rate. This study aims to evaluate early treatment with estradiol valerate on bone turnover markers after surgically induced menopause. Methods This prospective study included 41 pre and perimenopausal women who underwent hysterectomy with oophorectomy for benign gynecologic conditions. Two weeks after the operation, all participants were assessed for menopausal hormone therapy (MHT) indications. Estrogen therapy was prescribed for those who had indications and accepted treatment (hormone treatment group). The others who had no MHT indication were allocated to the no-treatment group. Serum CTX and P1NP levels at preoperative and 12 weeks postoperative were measured and set as the primary outcome. Within the same group, serum CTX and P1NP before and after surgical menopause were analyzed using Wilcoxon signed-rank test. ANCOVA was used to compare serum CTX and P1NP at 12 weeks after surgical menopause between the two groups. Spearman's rank correlation coefficient analysis analyzed the correlation between age and baseline bone turnover markers. A p-value of < 0.05 was considered statistically significant. Results At 12 weeks after surgery, there were no significant differences in serum CTX and P1NP levels in the hormone treatment group compared to baseline. In contrast, serum CTX and P1NP levels were significantly elevated among women who did not receive hormone treatment (p-value < 0.001 and 0.002, respectively). Serum CTX and P1NP at 12 weeks were significantly different between the two groups (p-value < 0.001 and 0.004, respectively). Conclusion Early estrogen administration with oral estradiol valerate could significantly suppress the high bone remodeling in surgically induced menopausal women. Trial registration Thai Clinical Trial Registry identification number TCTR20190808004, retrospective registered since 2019-08-08. http://www.thaiclinicaltrials.org/show/TCTR20190808004.

Download Full-text

Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women

Journal of Bone and Mineral Metabolism ◽

10.1007/s00774-013-0558-2 ◽

2014 ◽

Vol 33 (1) ◽

pp. 93-100 ◽

Cited By ~ 7

Author(s):

Shinichi Nagase ◽

Michiyo Ohyama ◽

Yoshitaka Hashimoto ◽

Maria Small ◽

John Sharpe ◽

...

Keyword(s):

Bone Turnover ◽

Sustained Release ◽

Bone Turnover Markers ◽

Cathepsin K ◽

Release Formulation ◽

Sustained Release Formulation ◽

Cathepsin K Inhibitor ◽

Menopausal Women ◽

Turnover Markers ◽

Post Menopausal

Download Full-text

Reversal of adverse effects of neoadjuvant chemotherapy on bone turnover in pre- and post-menopausal women with zoledronic acid

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.556 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 556-556

Author(s):

R. Aft ◽

M. Naughton ◽

K. Trinkuas ◽

M. Watson ◽

K. Weilbaecher

Keyword(s):

Zoledronic Acid ◽

Growth Factor ◽

Neoadjuvant Chemotherapy ◽

Bone Turnover ◽

Bone Turnover Markers ◽

Mineral Density ◽

Menopausal Women ◽

Turnover Markers ◽

Post Menopausal ◽

The Impact

556 Background: Ovarian failure secondary to adjuvant chemotherapy is known to have an adverse effect on bone mineral density and to increase bone turnover markers. The effects of chemotherapy with growth factor support in the absence of hormonal changes have not been described. The impact of zoledronic acid on these changes was also explored. Methods: We evaluated bone turnover markers in 82 women undergoing neoadjuvant chemotherapy for localized stage II/III breast cancer at initial diagnosis prior to treatment and after 4 cycles of epirubicin (75mg/m2)-docetaxel (75mg/m2) with pegylated G-CSF support with or without zoledronic acid. 47% of patients were post-menopausal and all groups were balanced for other variables. Women were randomized to receive zoledronic acid 4 mg IV every 3 weeks concurrently with chemotherapy (n=41) versus no bisphosphonate treatment (n=41). Bone turnover markers included: urinary N-telopeptide (NTx), serum bone specific alkaline phosphatase (BAP)and osteocalcin (OSTEO). Results: Women, regardless of menopausal status, who received no bisphosphonate had statistically significant increases in NTx, from baseline after 3 months of neoadjuvant chemotherapy using multivariable mixed repeated measures (p=0.0213). Women who received zoledronic acid concurrently with neoadjuvant chemotherapy had statistically significant decreases in NTx (p<0.0001), BAP (p<0.0001) and OSTEO (p=0.0295) from baseline. This is the first demonstration that anthracycline-taxane chemotherapy with growth factor support increased bone turnover markers in both post-menopausal and pre-menopausal women independent of hormone therapy, radiation therapy and surgery. Conclusions: Neoadjuvant chemotherapy with anthracycline- taxane and growth factor support increased bone resorption markers in both post-menopausal and pre-menopausal women. Zoledronic acid given concurrently with each cycle of chemotherapy reversed this increase in bone turnover markers. No significant financial relationships to disclose.

Download Full-text

Effects of Upper-Body Resistance Training on Bone Turnover Markers and Mineral Density in Pre-menopausal Women

Medicine & Science in Sports & Exercise ◽

10.1249/01.mss.0000400673.29563.d2 ◽

2011 ◽

Vol 43 (Suppl 1) ◽

pp. 246

Author(s):

Lorena Quezada ◽

Michael T.C. Liang ◽

Bülent Sökmen ◽

Thomas W. Spalding ◽

W.Y. Jamie Lau

Keyword(s):

Resistance Training ◽

Bone Turnover ◽

Bone Turnover Markers ◽

Upper Body ◽

Mineral Density ◽

Menopausal Women ◽

Body Resistance ◽

Turnover Markers

Download Full-text

A Double-Blind Placebo-Controlled Randomized Trial Evaluating the Effect of Polyphenol-Rich Herbal Congee on Bone Turnover Markers of the Perimenopausal and Menopausal Women

Oxidative Medicine and Cellular Longevity ◽

10.1155/2018/2091872 ◽

2018 ◽

Vol 2018 ◽

pp. 1-11 ◽

Cited By ~ 1

Author(s):

Jintanaporn Wattanathorn ◽

Woraluk Somboonporn ◽

Sudarat Sungkamanee ◽

Wipawee Thukummee ◽

Supaporn Muchimapura

Keyword(s):

Alkaline Phosphatase ◽

Bone Turnover ◽

Bone Turnover Markers ◽

Clinical Chemistry ◽

Controlled Study ◽

Total Phenolic ◽

Double Blind ◽

Double Blind Placebo ◽

Menopausal Women ◽

Turnover Markers

Based on the benefit of polyphenolic compounds on osteoporosis, we hypothesized that the polyphenol-rich herbal congee containing the combined extract of Morus alba and Polygonum odoratum leaves should improve bone turnover markers in menopausal women. To test this hypothesis, a randomized double-blind placebo-controlled study was performed. A total of 45 menopausal participants were recruited in this study. They were randomly divided into placebo, D1, and D2 groups, respectively. The subjects in D1 and D2 groups must consume the congee containing the combined extract of M. alba and P. odoratum leaves at doses of 50 and 1500 mg/day, respectively. At the end of an 8-week consumption period, all subjects were determined serum bone markers including calcium, alkaline phosphatase, osteocalcin, and beta CTX. In addition, the hematological and blood clinical chemistry changes, and total phenolic content in the serum were also determined. The results showed that the menopausal women in D2 group increased serum alkaline phosphatase, osteocalcin, and total phenolic compounds content but decreased CTX level. Clinical safety assessment failed to show toxicity and adverse effects. Therefore, herbal congee containing the combined extract of M. alba and P. odoratum leaves is the potential functional food that can decrease the risk of osteoporosis.

Download Full-text